Cite
HARVARD Citation
Ikeda, S. et al. (n.d.). A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism. 17 (10), pp. 984-993. [Online].